Phil Inc. Partners with RedHill Biopharma to Increase Access to Talicia®

Celldex Therapeutics, Inc. has initiated their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE) with the dosing of the first patient. EoE is a chronic inflammatory disease that affects the esophagus and is the most common form of eosinophilic gastrointestinal disease. The objective of this study is to assess the effectiveness and safety of subcutaneous barzolvolimab in patients w..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine

AbbVie has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for atogepant, an oral calcitonin gene-related peptide receptor antagonist, as a prophylaxis of migraine in adults who have four or more migraine days per month. If approved by the European Commission, AbbVie will be the only company to offer a once-daily treatment sp..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms